【レポートの概要（一部）】
1. Report Overview
1.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market Overview
1.2 The Alzheimer’s Disease Therapeutics and Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Alzheimer’s Disease: An Introduction
2.1 Neurodegenerative Diseases
2.1.1 What is Alzheimer’s Disease?
2.1.2 What Causes Alzheimer’s Disease?
2.1.2.1 Alzheimer’s Disease: Type 3 Diabetes?
2.1.3 Management of Alzheimer’s Disease
2.1.4 The Socio-Economic Impact of Alzheimer’s Disease
2.1.5 Diagnosis of Alzheimer’s Disease
3. Alzheimer’s Disease Therapeutics and Diagnostics Market 2016-2026
3.1 Alzheimer’s Disease Therapeutics and Diagnostics Market, 2015
3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition
3.2.2 Healthcare Costs for Alzheimer’s Disease Will Surpass All Other Medical Expenses
3.2.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
3.3 Drivers and Restraints
4. The Alzheimer’s Disease Drugs Market, 2016-2026
4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer’s disease
4.2 The Alzheimer’s Disease Drugs Market, 2015
4.3 Changing Market Shares of the Leading Alzheimer’s Disease Drugs, 2016-2026
4.4 The Alzheimer’s Disease Drugs Market Forecast 2016-2026
4.5 Namenda
4.5.1 Namenda Sales Forecast, 2016-2026
4.6 Aricept
4.6.1 Aricept Sales Forecast, 2016-2026
4.7 Exelon
4.7.1 Exelon Sales Forecast, 2016-2026
4.8 Alzheimer’s Disease Drugs Pipeline, 2015
4.8.1 New Guidelines: FDA to Relax Rules for the Approval of Alzheimer’s Drugs
4.8.2 Will Novel Drug Development Strategies Prove Successful?
4.8.3 Solanezumab (Eli Lilly)
4.8.3.1 Solanezumab Sales Forecast 2016-2026
4.8.4 Gantenerumab (Roche)
4.8.4.1 Gantenerumab Pipeline Forecast, 2015-2026
4.8.5 MK-8931 (Merck)
4.8.5.1 The MK-8931 Pipeline Forecast, 2015-2026
4.8.6 Lu AE58054 (Lundbeck)
4.8.7 TTP488 (TransTechPharma)
4.8.8 LMTX (TauRx)
4.8.9 EVP-6124 (Forum Pharmaceuticals)
4.8.10 Axona (Accera)
4.8.11 AD-4833 (Takeda Pharmaceuticals)
4.9 Deep Brain Stimulation (Functional Neuromodulation)
4.10 Recent Research on Alzheimer’s Disease
5. Leading Companies in the Alzheimer’s Disease Drugs Market, 2015
5.1 Pfizer, Inc
5.1.1 Sales and Recent Performance Analysis, 2015
5.1.2 Pfizer: Aricept
5.1.3 Pfizer: R&D Capabilities and Alzheimer’s Disease Drug Candidates
5.2 Eisai
5.2.1 Sales and Recent Performance Analysis, 2015
5.2.2 Eisai: Aricept
5.2.3 Eisai: R&D Capabilities and Alzheimer’s Disease Drug Candidates
5.2.4 Collaboration with Biogen
5.2.5 Partnership with GE Healthcare for Diagnostic Development
5.3 Forest Laboratories (Acquired by Actavis)
5.3.1 Acquisition by Actavis
5.3.2 Forest: Namenda
5.3.3 Namenda’s Sales and Recent Performance Analysis, 2014
5.4 Lundbeck A/S
5.4.1 Sales and Recent Performance Analysis, 2014
5.4.2 Lundbeck: R&D Capabilities
5.4.3 Lundbeck’s Alzheimer’s Disease Drug Pipeline
5.4.4 Lundbeck: Ebixa
5.5 Daiichi Sankyo
5.5.1 Financial Sales and Recent Performance, 2015
5.5.2 Daiichi Sankyo: Memary
5.6 Novartis AG
5.6.1 Sales and Recent Performance Analysis
5.6.2 Novartis: Exelon
5.6.3 eHealth Programme Delivering Innovation
5.6.4 Novartis: Alzheimer’s Disease Drug Pipeline
5.7 TauRx
5.7.1 Partnership with Bayer Schering Pharma AG
5.8 vTv Therapeutics
5.8.1 TTP Translational Technology
5.8.2 vTv Therapeutics: Alzheimer’s Disease Pipeline Portfolio
6. The Alzheimer’s Disease Diagnostics Market, 2015-2026
6.1 There is Still a Strong Market Need for Effective Diagnosis
6.2 The Alzheimer’s Disease Diagnostics Market, 2015
6.3 Changing Market Shares of Leading Alzheimer’s Diagnostic Markets, 2015-2026
6.4 The Alzheimer’s Diagnostics Market, 2015-2026
6.5 New Criteria and Guidelines to Diagnose Alzheimer’s Disease
6.6 Biomarkers for Alzheimer’s Disease
6.6.1 Leading Companies Pursuing Novel Biomarker Development Strategies
6.7 Alzheimer’s Disease: Advances in Diagnostic Imaging Technologies
6.7.1 Structural Imaging
6.7.2 Functional Imaging
6.7.3 Molecular Imaging Technologies
6.7.3.1 Pittsburgh Compound B (PIB) (GE Healthcare)
6.7.3.2 Florbetapir F18 (18F-AV-45) (Eli Lilly)
6.7.3.3 Flutemetamol (GE Healthcare)
6.7.3.4 Florbetaben (Piramal Imaging)
6.8 Other Alzheimer’s Diagnostics in Development
6.8.1 CSF Proteins
6.8.2 Blood Based Biomarkers for Alzheimer’s Disease
6.8.3 Genetic Risk Profiling
6.8.4 Eye Tests
6.8.5 Nanoparticles
6.9 Leading Companies in the Alzheimer’s Disease Diagnostics Market, 2015
6.9.1 Eli Lilly
6.9.1.1 Recent Performance and Sales Analysis, 2015
6.9.1.2 Alzheimer’s Disease Research Effort
6.9.1.3 Solanezumab
6.9.1.4 Amyvid (Florbetapir F18)
6.9.1.5 Amyvid Receives Marketing Authorization from the European Commission
6.9.1.6 LY-2886721: Terminated Drug
6.9.1.7 LY3002813: Phase I
6.9.1.8 Eli Lilly Acquires Novel Tau Tangle Diagnostic Programme
6.9.2 Amarantus BioScience Holdings, Inc.
6.9.2.1 Recent Performance and Sales Analysis, 2014
6.9.2.2 LymPro
6.9.2.3 Intellectual Property Acquisitions
6.9.3 Piramal Enterprises
6.9.3.1 Piramal Imaging SA
6.9.3.2 U.S. and EMA Approval of Florbetaben
6.9.3.3 Manufacturing and Distribution Agreements
6.9.4 GE Healthcare
6.9.4.1 GE’s Commitment to Imaging Research in the Alzheimer’s Field
6.9.4.2 Regulatory Approval of Flutemetamol
6.9.4.3 Licensing Agreements for Flutemetamol
6.9.5 Navidea
6.9.5.1 NAV4694 (Fluorine-18)
6.9.5.2 Collaboration Agreements
6.9.5.3 NAV4694 Clinical Development
6.9.6 DiaGenic
7. The Leading National Markets, 2015-2026
7.1 Regional Breakdown of the Global Alzheimer’s Disease Therapeutics and Diagnostic Market, 2015
7.1.1 The US, Japan and Europe Represent More than 80% of the Total Market
7.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Regional Forecast, 2015-2026
7.3 Changing Market Shares of Leading National Markets 2015-2026
7.4 The US Alzheimer’s Disease Therapeutics and Diagnostics Market, 2015-2026
7.4.1 One in Nine Over the Age of 65 has AD in the US
7.4.2 The US Will Remain the Largest Market Over the Forecast Period
7.5 The European Alzheimer’s Disease Therapeutics and Diagnostics Market, 2015-2026
7.5.1 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.2 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.3 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.4 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.5 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.6 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.6 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.7 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.8 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.9 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.10 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.11 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
8. Qualitative Analysis of the Alzheimer’s Disease: Therapeutics and Diagnostics Market, 2016-2026
8.1 SWOT Analysis
8.2 Strengths
8.2.1 Alzheimer’s Disease is a High Profile Disease
8.2.2 Expanding Patient Population
8.2.3 Strong R&D Pipeline in Both Sectors of the Market
8.3 Weaknesses
8.3.1 Current Drugs Only Treat the Symptoms of Alzheimer’s Disease
8.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials
8.3.3 Poor Macroeconomic Conditions in Key Regions of the Market
8.4. Opportunities
8.4.1 Regulations Seeking Improved Standards of Alzheimer’s Disease Drug Development
8.4.2 Neurodegenerative Diseases Have Strong R&D
8.4.3 Emerging Markets Will Help Drive the Market
8.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration
8.5 Threats
8.5.1 Patent Expiries Will Lead to Further Generic Competition
8.5.2 New AD Therapies Face Political, Commercial and Social Pressures
8.6 Porter’s Five Force Analysis
8.6.1 Rivalry Among Competitors
8.6.2 Threats of New Entrants
8.6.3 Powers of Suppliers
8.6.4 Bargaining Power of Buyers
8.6.5 Threat of Substitutes
9. Research Interviews from Our Survey
9.1 Mr. Timothy Earle, Chief Operating Officer / Chief Business Officer, TauRx Pharmaceuticals Ltd
9.1.1 Alzheimer’s Treatment in Late Stage Development
9.1.2 Alzheimer’s Severe Under diagnosis
9.1.3 The Benefits of Alzheimer’s Diagnosis: A Future Prospect
9.1.4 Alzheimer’s Treatment: The Greatest Challenge
9.2 Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
9.2.1 Ultra Sensitive Automated Immunoassay Platform for Alzheimer’s
9.2.2 Alzheimer’s Disease Diagnosis Biomarkers
9.2.3 Quanterix: Future Developments
9.3 The Alzheimer’s Association Northern California and Northern Nevada
9.3.1 Alzheimer’s Treatment in Late Stage Development
9.3.2 Novel Biomarkers: Critical for Alzheimer’s Diagnosis
9.3.3 A Push to Improve the Success of Alzheimer’s Research
10. Conclusion
10.1 Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs
10.2 Disease Modifying Drugs Will Transform the Declining Alzheimer’s Market
10.3 Demographics Will Help Drive the Market Over the Forecast Period
10.4 Medicines and Diagnostic Tests for Alzheimer’s Disease Hold Great Potential from 2015 to 2026
10.5 Research for Alzheimer’s Happening all Over the World
【レポート販売概要】
■ タイトル：アルツハイマー病治療・診断の世界市場予測2016-2026■ 英文：Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026
■ 発行日：2016年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN60625
■ 調査対象地域：グローバル
- Mobile VoIP: Technology and BusinessThis report examines the technical, regulatory and business aspects of VoIP on mobile networks (MVoIP). Itanalyzes the key aspects of the HSPA, HSPA+ and LTE technology and highlights its challenges and opportunities. It evaluates current standardization efforts in 3GPP bodies on IMS and VoLGA and the status of regulatory requirements in different countries. The business impact of each of the tech …
- 主変圧器の世界市場ABSTRACTAbout Traction Transformers Traction transformers are special application transformers that are integral to the electric traction system. It converts the supplied electrical energy into usable electrical energy, to power electric motors within a locomotive engine, high-speed trains, and trams to generate motive force. Technavio’s analysts forecast the global traction transformers market to …
- 高級アイウェアのグローバル市場動向The global market for optics and eye wear is expected to expand at the rate of 6% in the coming five years ahead and will go on to account for a total of $20 billion in revenues. It is expected that the sunglass market will benefit not only from increased awareness of the dangers of UV exposure but also from frames and sunglasses being increasingly perceived as fashion products. Innovative materia …
- 世界の顧客向けクラウドサービス（アプリケーション）市場動向（2014～2018）TechNavio's analysts forecast the Global Customer Cloud App market to grow at a CAGR of 15.25 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increased need for effective storage. The Global Customer Cloud App market has also been witnessing that the increasing number of vendors leads to a decrease in the cost of cloud applications. However, the …
- 世界の石油増進回収法(EOR)市場予測：熱攻法、ガス圧入法、ケミカル法Enhanced oil recovery (EOR) technologies are used to increase the amount of oil that can be extracted from an oil field after the primary and secondary production stages. The technologies play on the physics of how oil is trapped in the rocks and are primarily aimed at either decreasing the interfacial forces holding the oil in pores within the rock formation, reducing the viscosity difference bet …
- 強直性脊椎炎の疫学的予測EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024 Summary Ankylosing spondylitis (AS) - a systemic, chronic, and progressive inflammatory arthritis, is the prototype of a family of related disorders known as seronegative spondyloarthritis (SpA) and one of the most common rheumatic diseases across the globe. AS primarily affects the spine and sacroiliac (SI) joints and progress …
- 特発性肺線維症(Idiopathic Pulmonary Fibrosis)：治療薬開発パイプライン動向（2015年上半期版）Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015’, provides an overview of the Idiopathic Pulmonary Fibrosis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, t …
- 胸部外科手術の世界市場2016-2020About Thoracic Surgery Thoracic surgery involves surgical treatment (open surgery or minimally invasive surgery) to address medical conditions involving the heart or lungs. It includes procedures such as redo heart surgery, aortic dissection for aortic surgery, minimally invasive mitral valve repair and replacement, and endovascular repair of thoracic aortic aneurysms. It is performed to treat end …
- 充填クロマトグラフィーカラムの世界市場Pre-packed columns market has been pegged at $1.3b in the year 2013 growing at 5.6% annually and is projected to reach $1.8b by the end of the year 2018. Pre-packed columns constitute 90.3% of Global Columns market and are poised to grow its market share to 91.0% by the end of year 2018. Peers of Hydrocolloids are Empty columns comprising 9.7% respectively of the Global Columns market. It is segme …
- セイボリー菓子の世界市場2017-2021ABSTRACTAbout Savory Snacks Savory snacks come under the snack foods category, which have a salty taste and are different from sweet snacks. The global savory snacks market can be divided into eight major categories: potato chips, extruded snacks, nuts and seeds, frozen potato snacks, ethnic/traditional snacks, popcorn, meat snacks, and other savory snack products. Technavio’s analysts forecast th …
- ウェアラブルセンサーの世界市場：センサーのタイプ別（光センサー、圧力センサー、温度センサー、医療ベースセンサー）、デバイス別（スマートウォッチ、フィットネスバンド、スマートメガネ、スマートファブリック）、業種別（消費財、防衛、ヘルスケア、その他）、地域別予測Global Wearable Sensors Market to reach USD XXX billion by 2025. Global Wearable Sensors Market valued approximately USD XXX billion in 2016 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2017-2025. Sensors are a vital aspect in wearable devices used by consumers owing to increased focus on tracking real-time motion sensing activities. This is likely to …
- 癌治療用バイオシミラーの世界市場機会Cancer incidences are escalating tremendously across the globe due to which burgeoning pressure has been created on pharmaceutical companies to come forth with viable products. Moreover, presently available drugs for cancer treatment are known for their superior pharmacological benefits along with their significantly higher prices. Most of the cancer patients are unable to afford them due to finan …
- フェイシャルケア製品の世界市場2016-2020About Facial Care Products Facial care products include day creams, night creams, masks, serums, cleansers, and toners. These products are used to enhance the skin quality, rejuvenate the cells, prevent wrinkles, and brighten the skin. Modern-day lifestyle changes such as physical inactivity, stress, lack of sleep, excess fast food consumption, and limited water intake are leading to a growing num …
- 半導体資本設備の世界市場2019-2023About this market Owing to the rising need for semiconductor memory devices due to the rapidly advancing dynamics of consumer electronics, the semiconductor memory devices market demand is expected to rise throughout the forecast period. Technavio’s analysts have predicted that the semiconductor capital equipment market will register a CAGR of more than 6% by 2023. Market Overview Rising number of …
- インドのシリカフューム市場：用途別、ソース別Silica Fume Market in India: About this market Technavio’s silica fume market in India analysis considers sales from construction, marine, oil and gas, and other applications. Our study also finds the sales of silica fume from silicon metal and ferrosilicon sources. In 2019, the construction segment had a significant market share, and this trend is expected to continue over the forecast period. Fa …
